JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

Pfizer

Затворен

СекторЗдравеопазване

24.67 1.52

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.59

Максимум

24.71

Ключови измерители

By Trading Economics

Приходи

-45M

2.9B

Продажби

938M

15B

P/E

Средно за сектора

13.106

37.003

EPS

0.78

Дивидентна доходност

6.87

Марж на печалбата

19.982

Служители

81,000

EBITDA

266M

5.3B

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+16.02% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

6.87%

2.25%

Следващи печалби

4.11.2025 г.

Следваща дата на дивидент

1.12.2025 г.

Следваща дата на екс-дивидент

7.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

7.1B

141B

Предишно отваряне

23.15

Предишно затваряне

24.67

Настроения в новините

By Acuity

45%

55%

150 / 373 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

Pfizer Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.10.2025 г., 12:38 ч. UTC

Придобивния, сливания и поглъщания

Novo Nordisk Seeks to Outmuscle Pfizer With Up to $9 Billion Bid for Metsera -- 2nd Update

30.10.2025 г., 11:03 ч. UTC

Придобивния, сливания и поглъщания

Novo Nordisk Seeks to Muscle Out Pfizer With Up to $9 Billion Bid for Metsera -- Update

31.10.2025 г., 22:44 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31.10.2025 г., 21:25 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Pfizer Says Novo Nordisk's Metsera Bid Won't Pass Antitrust Laws -- Market Talk

31.10.2025 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- Update

31.10.2025 г., 21:12 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Sues Metsera, Novo Nordisk, Claiming Novo Nordisk Takeover Offer Isn't Superior -- WSJ

31.10.2025 г., 21:12 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31.10.2025 г., 21:12 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Seeks Order Blocking Metsera From Terminating Its Merger Deal With Pfizer -- WSJ

31.10.2025 г., 20:46 ч. UTC

Придобивния, сливания и поглъщания

Pfizer: Files Lawsuit Against Metsera and Its Directors and Novo Nordisk for Breach of Merger Agreement

31.10.2025 г., 19:54 ч. UTC

Придобивния, сливания и поглъщания

Pfizer: FTC Granted Early Termination of Waiting Period >PFE

31.10.2025 г., 19:54 ч. UTC

Придобивния, сливания и поглъщания

Pfizer: Receives Early Clearance From FTC for Metsera Acquisition

31.10.2025 г., 13:49 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Novo Nordisk's Move for Metsera Looks Defensive -- Market Talk

31.10.2025 г., 12:20 ч. UTC

Печалби

AbbVie Beats Third-Quarter Estimates. There's More to the Drugmaker's Earnings. -- Barrons.com

30.10.2025 г., 18:11 ч. UTC

Придобивния, сливания и поглъщания

Novo Nordisk Tries to Snatch a Weight-Loss Biotech From Pfizer. There Are Political Risks. -- Barrons.com

30.10.2025 г., 16:52 ч. UTC

Придобивния, сливания и поглъщания

Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera -- WSJ

30.10.2025 г., 16:52 ч. UTC

Придобивния, сливания и поглъщания

Metsera Was Previously in Exclusive Talks with Bristol-Myers Squibb, Sources Say -- WSJ

30.10.2025 г., 15:09 ч. UTC

Придобивния, сливания и поглъщания

Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker. -- Barrons.com

30.10.2025 г., 14:00 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Metsera, Pfizer Debate Superiority of Novo Bid -- Market Talk

30.10.2025 г., 13:49 ч. UTC

Печалби

Merck Stock Falls. Sales of Key Products Missed Estimates. -- Barrons.com

30.10.2025 г., 13:44 ч. UTC

Придобивния, сливания и поглъщания

Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera -- 4th Update

30.10.2025 г., 13:39 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Novo Nordisk's Pursuit of Metsera Could Be a Sore Loss For Pfizer -- Market Talk

30.10.2025 г., 13:22 ч. UTC

Печалби

Eli Lilly Stock Rises on Earnings as Investors Await Trump Drug Pricing Deal -- Barrons.com

30.10.2025 г., 13:22 ч. UTC

Придобивния, сливания и поглъщания

Novo Nordisk Seeks to Outmuscle Pfizer With $9 Billion Bid for Metsera -- 3rd Update

30.10.2025 г., 12:42 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Pfizer Raises Antitrust Issues With Novo's Metsera Bid -- Market Talk

30.10.2025 г., 12:37 ч. UTC

Придобивния, сливания и поглъщания

Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker. -- Barrons.com

30.10.2025 г., 11:13 ч. UTC

Печалби

Eli Lilly Stock Rises on Earnings as Investors Await Trump Drug Pricing Deal -- Barrons.com

30.10.2025 г., 11:11 ч. UTC

Придобивния, сливания и поглъщания

Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker. -- Barrons.com

30.10.2025 г., 11:10 ч. UTC

Придобивния, сливания и поглъщания

Metsera: May Negotiate With Pfizer on Potential Adjustments to Transaction >MTSR PFE

30.10.2025 г., 11:09 ч. UTC

Придобивния, сливания и поглъщания

Metsera: Pfizer Merger Agreement Remains in Effect >MTSR PFE

30.10.2025 г., 11:09 ч. UTC

Придобивния, сливания и поглъщания

Metsera: Board Determines Novo Nordisk Bid Constitutes Superior Proposal as Defined in Merger Pact With Pfizer >MTSR

Сравнение с други в отрасъла

Ценова промяна

Pfizer Прогноза

Ценова цел

By TipRanks

16.02% нагоре

12-месечна прогноза

Среден 28.6 USD  16.02%

Висок 34 USD

Нисък 24 USD

Според 17 анализатори от Wall Street, предложили 12-месечна ценова цел за Pfizer през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

17 ratings

4

Купи

12

Задържане

1

Продай

Техническа оценка

By Trading Central

22.855 / 23.85Подкрепа & съпротива

Краткосрочен план

Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

150 / 373 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat